Dermapharm Holding SE (0A5J.IL)
IOB · EUR · Healthcare · Drug Manufacturers - Specialty & Generic
€38.25 (-0.52%) as of
Key statistics
- Market cap
- 2.11B
- P/E (TTM)
- 16.78
- EPS (TTM)
- 2.28
- Dividend yield
- 2.75%
- 52-week range
- 32.50 – 51.70
- Beta
- 1.13
- Revenue (TTM)
- 1.15B
- Profit margin
- 10.65%
- Volume
- 29.00
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany and internationally. It operates through three segments: Branded Pharmaceuticals and Other Healthcare Products, Parallel Import Business, and Herbal Extracts. The company develops, manufactures, licenses, markets, and sells branded generics, over-the-counter drugs, non-prescription healthcare products, herbal extracts, and other pharmaceutical products. It offers healthcare products in the areas of vitamins, minerals, food supplements, dermatology, allergology, pain and inflammation treatment, cardiovascular support, gynecology, and urology. The company also provides medical devices under the bite away and Herpotherm names. Further, it imports originator pharmaceuticals under the axicorp brand; and offers herbal extracts and natural active ingredients for phytopharmaceuticals, nutraceuticals, and cosmetics. The company was founded in 1991 and is based in Grünwald, Germany. Dermapharm Holding SE operates as a subsidiary of Themis Beteiligungs-AG.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - Specialty & Generic
- Headquarters
- Grünwald, Germany
- Employees
- 3,404
Financial statements (income statement, balance sheet, cash flow) and an interactive price chart are available on this page with JavaScript enabled.